Regulatory Affairs Specialist
ROLE DEFINITION & RESPONSIBILITIES
A Regulatory Affairs (RA) Specialist coordinates the legal, regulatory, and technical interface between pharmaceutical/biotech companies and government health authorities. They ensure products comply with health laws, prepare and submit investigational (IND) and marketing authorization dossiers (NDA/BLA/ANDA), and manage post-approval life-cycle variations and labeling changes.
SALARY INTELLIGENCE ROADMAP
LEARNING PATHWAYS
Global Regulatory Landscapes & Frameworks
Examine FDA (21 CFR), EMA Directives, PMDA Japan, and CDSCO Indian regulatory frameworks.
Chemistry, Manufacturing & Controls (CMC)
Master Module 3 compilation, stability testing (ICH Q1A), validation protocols, and specification limits.
eCTD Publishing & Submission Validation
Build electronic dossiers with valid XML backbones, hyperlinks, bookmarks, and checksums using publishing suites.
Post-Approval Changes & Regulatory Strategy
Manage variations (Type IA, IB, II / Prior Approval Supplements), labeling updates, and sunset reviews.
CONNECTED ZANE PROED ACADEMY COURSES
Clinical Research & GCP Standards Masterclass
Become certified under international ICH-GCP regulatory parameters.
VERIFIED INTERVIEW PREPARATION
> Q: Can you describe the structure of the Common Technical Document (CTD)?
The CTD format consists of five modules: Module 1 is regional administrative information (specific to each health authority). Module 2 is CTD summaries (Quality, Nonclinical, Clinical). Module 3 is Quality (CMC information on drug substance and drug product). Module 4 is Nonclinical Study Reports. Module 5 is Clinical Study Reports.
> Q: What is the difference between an NDA (New Drug Application) and an ANDA (Abbreviated New Drug Application)?
An NDA is submitted for brand-new, innovator chemical entities and requires complete preclinical safety and clinical efficacy trials (Modules 1-5). An ANDA is submitted for generic drug products and does not require new preclinical or clinical trials; instead, it proves bioequivalence to the Reference Listed Drug (RLD).